Rosetta Genomics to Present at the 27th Annual ROTH Conference
March 04 2015 - 8:31AM
Business Wire
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics, announces that
Company management will participate in the upcoming 27th Annual
ROTH Conference being held from March 8-11, 2015 at the Ritz
Carlton, Laguna Niguel in Dana Point, Calif. Ken Berlin, Rosetta’s
President and Chief Executive Officer, will present a corporate
overview and update on March 10, 2015 at 5:30 p.m. Pacific
time.
A live audio webcast of Mr. Berlin’s presentation will be
available in the investor section of Rosetta Genomics’ website,
http://www.rosettagenomics.com, where it will also be archived for
30 days.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based molecular diagnostics. Founded in 2000, Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Rosetta’s cancer testing
services are commercially available through its Philadelphia-based
CAP-accredited, CLIA-certified lab.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects, including without limitation,
Rosetta’s development or commercialization of molecular diagnostics
or therapeutics, the market acceptance of Rosetta’s cancer testing
services, particularly the Rosetta Cancer Origin Test™ and the
thyroid assay, Rosetta’s development of personalized medicine
products and services, constitute forward-looking statements for
the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, including those risks
more fully discussed in the "Risk Factors" section of Rosetta’s
Annual Report on Form 20-F for the year ended December 31,
2013 as filed with the SEC. In addition, any forward-looking
statements represent Rosetta’s views only as of the date of this
release and should not be relied upon as representing its views as
of any subsequent date. Rosetta does not assume any obligation to
update any forward-looking statements unless required by law.
Company:Rosetta GenomicsKen Berlin, 609-419-9003President
& CEOinvestors@rosettagenomics.comorInvestors:LHAAnne
Marie Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024